Related Experiment Video

Updated: Oct 15, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.4K

Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure

Kohei Fujita1, Makoto Nakao1, Sosuke Arakawa1

  • 1Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Japan.

Journal of Rural Medicine : JRM
|October 28, 2021
PubMed

Insights

Topotecan monotherapy showed no response in relapsed small-cell lung cancer (SCLC) patients previously treated with amrubicin. Further research is needed to determine its effectiveness and safety in this patient population.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Relapsed small-cell lung cancer (SCLC) after amrubicin treatment presents a therapeutic challenge.
  • The efficacy of topotecan monotherapy in this specific clinical scenario remains unevaluated.

Purpose of the Study:

  • To assess the efficacy and safety of topotecan monotherapy in patients with relapsed SCLC following amrubicin monotherapy.

Main Methods:

  • Retrospective analysis of 16 patients with relapsed SCLC.
  • Patients received topotecan monotherapy after prior amrubicin treatment.

Main Results:

  • No response was observed (response rate = 0%).
  • Median progression-free survival was 32.5 days; median overall survival was 112 days.
  • Common grade ≥3 adverse events included leukopenia (31.3%) and thrombocytopenia (31.3%).

Conclusions:

  • Topotecan monotherapy demonstrates inconclusive efficacy for relapsed SCLC after amrubicin failure.
  • Further clinical studies are warranted to clarify the role of topotecan in this setting.
Keywords:
amrubicinrelapsedsmall-cell lung cancertopotecan

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

2.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K